ArticleRSC advances2020
1-Phenyl-
Min-Qi Hu, Heng Li, Ying Lin, Ying Zhang, Jie Tang, Jian-Ping Zuo, Li-Fang Yu, Xian-Kun Tong, Wei Tang, Fan Yang
Abstract read
In one paragraphArticle in RSC advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Min-Qi HuShanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University Shanghai 200062 China fyang@chem.ecnu.edu.cn.
Heng LiShanghai Institute of Materia Medica, Chinese Academy of Sciences Shanghai 201203 China tangwei@simm.ac.cn xktong@simm.ac.cn.
Ying LinShanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University Shanghai 200062 China fyang@chem.ecnu.edu.cn.
Ying ZhangShanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University Shanghai 200062 China fyang@chem.ecnu.edu.cn.
Jie TangShanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University Shanghai 200062 China fyang@chem.ecnu.edu.cn.
Jian-Ping ZuoShanghai Institute of Materia Medica, Chinese Academy of Sciences Shanghai 201203 China tangwei@simm.ac.cn xktong@simm.ac.cn.
Li-Fang YuShanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University Shanghai 200062 China fyang@chem.ecnu.edu.cn.ORCID https://orcid.org/0000-0002-3250-6773 Xian-Kun TongShanghai Institute of Materia Medica, Chinese Academy of Sciences Shanghai 201203 China tangwei@simm.ac.cn xktong@simm.ac.cn.
Wei TangShanghai Institute of Materia Medica, Chinese Academy of Sciences Shanghai 201203 China tangwei@simm.ac.cn xktong@simm.ac.cn.
Fan YangShanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University Shanghai 200062 China fyang@chem.ecnu.edu.cn.ORCID https://orcid.org/0000-0002-0411-7391 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Middle East respiratory syndrome coronavirus (MERS-CoV) poses a serious threat to human health, and currently there are no effective or specific therapies available to treat it. Herein a series of 1-phenyl-
Identifiers
PMID35519683
PMCPMC9058255
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390